赛庚啶的滥用：刚果民主共和国金沙萨人群中的一种非传染性疾病风险行为。

The misuse of Cyproheptadine: a non-communicable disease risk behaviour in Kinshasa population, Democratic Republic of Congo.

作者信息

Lulebo Aimée M, Bavuidibo Carine D, Mafuta Eric M, Ndelo Josaphat D, Mputu Lievin's Corneille M, Kabundji Dalton M, Mutombo Paulin B

机构信息

Kinshasa School of Public Health, School of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo.

Department of Epidemiology and Biostatistics, Kinshasa School of Public Health, School of Medicine, University of Kinshasa, Po Box 11850, Kinshasa, Democratic Republic of the Congo.

出版信息

Subst Abuse Treat Prev Policy. 2016 Feb 9;11:7. doi: 10.1186/s13011-016-0051-8.

DOI:10.1186/s13011-016-0051-8

PMID:26860431

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4748556/

Abstract

BACKGROUND

Obesity is one of the main risk factors of non-communicable diseases (NCDs) worldwide, especially in sub-Saharan Africa. The use of Cyproheptadine increases body weight and the risk of becoming obese. The aim of this study is to determine the prevalence of Cyproheptadine misuse in the Kinshasa population and to describe its characteristics.

METHODS

A cross-sectional study was conducted in two town sectors of Kinshasa, Democratic Republic of Congo (DRC), over a 4 month period (May 2011 to August 2011). Data from 499 participants, aged between 13 and 55 years were collected and analyzed. Mean and standard deviation were used for quantitative variables and frequency and percentage for categorical variables. In order to determine the relationship between socio-demographic status and Cyproheptadine use the Chi-square test was conducted. Student's t-test was used to compare means age of Cyproheptadine users and non-users. Logistic regression was used to determine predictors of Cyproheptadine use. A p-value of <0.05 was considered statistically significant.

RESULTS

Overall, 499 participants were enrolled (352 females, 147 males, mean age ± standard deviation 24.9 ± 9.7 years) in the study. The majority of the study participants (72.9 %) had used Cyproheptadine as an appetite stimulant. Females were 11 times more likely to use Cryproheptadine (OR = 11.9; 95 % CI: 7.1-20.1) than males. People aged between 36 and 55 were three times less likely to use Cryproheptadine (OR = 0.3; 95 % CI: 0.2-0.8) compared to teenagers. More than half of the participants (69.0 %) declared to take daily Cyproheptadine. Half of the study participants (50.0 %) used Cyproheptadine for more than a year and also declared to combine it with Dexamethasone (87.6 %).

CONCLUSION

This study shows that the Kinshasa population is significantly misusing Cyproheptadine and is highly exposed to its risk, including obesity.

摘要

背景

肥胖是全球非传染性疾病（NCDs）的主要风险因素之一，在撒哈拉以南非洲地区尤为突出。使用赛庚啶会增加体重和肥胖风险。本研究的目的是确定金沙萨人群中赛庚啶滥用的患病率，并描述其特征。

方法

在刚果民主共和国（DRC）金沙萨的两个城镇地区进行了一项为期4个月（2011年5月至2011年8月）的横断面研究。收集并分析了499名年龄在13至55岁之间参与者的数据。定量变量使用均值和标准差，分类变量使用频率和百分比。为了确定社会人口学状况与赛庚啶使用之间的关系，进行了卡方检验。使用学生t检验比较赛庚啶使用者和非使用者的平均年龄。使用逻辑回归确定赛庚啶使用的预测因素。p值<0.05被认为具有统计学意义。

结果

总体而言，本研究共纳入499名参与者（352名女性，147名男性，平均年龄±标准差24.9±9.7岁）。大多数研究参与者（72.9%）将赛庚啶用作食欲刺激剂。女性使用赛庚啶的可能性是男性的11倍（OR = 11.9；95% CI：7.1 - 20.1）。与青少年相比，36至55岁的人使用赛庚啶的可能性低三倍（OR = 0.3；95% CI：0.2 - 0.8）。超过一半的参与者（69.0%）宣称每天服用赛庚啶。一半的研究参与者（50.0%）使用赛庚啶超过一年，并且还宣称将其与地塞米松联合使用（87.6%）。